Iterum Therapeutics Plc (NASDAQ: ITRM) has experienced a rise in its stock price by 13.87 compared to its previous closing price of 0.92. However, the company has seen a fall of -2.78% in its stock price over the last five trading days. globenewswire.com reported 2025-05-06 that DUBLIN, Ireland and CHICAGO, May 06, 2025 (GLOBE NEWSWIRE) — Iterum Therapeutics plc (Nasdaq: ITRM) (Company), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that the Company will release its first quarter 2025 financial results before the open of the U.S. financial markets on Tuesday, May 13, 2025. Management will host a conference call at 8:30 a.m.
Is It Worth Investing in Iterum Therapeutics Plc (NASDAQ: ITRM) Right Now?
ITRM has 36-month beta value of 2.88. Analysts have mixed views on the stock, with 0 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for ITRM is 37.88M, and currently, short sellers hold a 3.28% ratio of that float. The average trading volume of ITRM on May 09, 2025 was 382.87K shares.
ITRM’s Market Performance
The stock of Iterum Therapeutics Plc (ITRM) has seen a -2.78% decrease in the past week, with a -5.41% drop in the past month, and a -29.53% fall in the past quarter. The volatility ratio for the week is 9.15%, and the volatility levels for the past 30 days are at 8.29% for ITRM. The simple moving average for the past 20 days is -5.91% for ITRM’s stock, with a -23.92% simple moving average for the past 200 days.
Analysts’ Opinion of ITRM
H.C. Wainwright, on the other hand, stated in their research note that they expect to see ITRM reach a price target of $2.50. The rating they have provided for ITRM stocks is “Buy” according to the report published on March 15th, 2021.
RBC Capital Mkts gave a rating of “Sector Perform” to ITRM, setting the target price at $2 in the report published on June 02nd of the previous year.
ITRM Trading at -14.93% from the 50-Day Moving Average
After a stumble in the market that brought ITRM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -65.23% of loss for the given period.
Volatility was left at 8.29%, however, over the last 30 days, the volatility rate increased by 9.15%, as shares sank -6.25% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -25.00% lower at present.
During the last 5 trading sessions, ITRM fell by -2.78%, which changed the moving average for the period of 200-days by -13.93% in comparison to the 20-day moving average, which settled at $1.1159. In addition, Iterum Therapeutics Plc saw -40.68% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for ITRM
The total capital return value is set at -0.69. Equity return is now at value -555.68, with -69.93 for asset returns.
Based on Iterum Therapeutics Plc (ITRM), the company’s capital structure generated 1.1 points at debt to capital in total, while cash flow to debt ratio is standing at -0.59. The debt to equity ratio resting at -11.16. The interest coverage ratio of the stock is 7.41.
Currently, EBITDA for the company is -18.7 million with net debt to EBITDA at -1.15. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.41.
Conclusion
To put it simply, Iterum Therapeutics Plc (ITRM) has had a bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
